52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
U.S. FDA Says Announcing Project Orbis, An Initiative Of The FDA Oncology Center Of Excellence
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA
Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The other segment consists of pharmaceutical raw materials, logistics services and business services businesses.
Biotechnology & Drugs
Eisai Main Bldg., 4-6-10, Koishikawa
Chairman of the Board of Directors, Independent Director
Chief Executive Officer, Representative Executive Officer, Director
Managing Executive Officer, Chief Financial Officer, Chief IR Officer
Representative Executive Officer, Chief Information Officer
Executive Officer, Chief Compliance Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.
Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.
Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.
Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.
Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.
Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.
Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.
(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)
The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.
Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)
Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.
Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.
Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.
* Says it forms business and capital alliance with Eisai Co Ltd
* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC
(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)
* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)
Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses.
* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.